Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency
A Cohen, R Hirschhorn, S D Horowitz, A Rubinstein, S H Polmar, R Hong, D W Martin Jr, A Cohen, R Hirschhorn, S D Horowitz, A Rubinstein, S H Polmar, R Hong, D W Martin Jr
Abstract
The inherited deficiency of adenosine deaminase (adenosine aminohydrolase; EC 3.5.4.4) activity in humans is associated with an immunodeficiency. Some of the immunodeficient and enzyme-deficient patients respond immunologically to periodic infusions of irradiated erythrocytes containing adenosine deaminase. It has been previously reported that erythrocytes and lymphocytes from immunodeficient ane enzyme-deficient children contained increased concentrations of ATP, and in the one child studied after erythrocyte infusion therapy, the intracellular level of ATP diminished. Using high-pressure liquid chromatography that resolves ATP and 2'-dATP, we have observed greater than 50-fold elevations of dATP in the erythrocytes of immunodeficient, adenosine deaminase-deficient patients but not in the erythrocytes of an immunocompetent adenosine deaminase-deficient patient. The erythrocyte dATP in two unrelated adenosine deaminase-deficient, immunodeficient patients disappeared after infusion of normal erythrocytes. We propose that deoxyadenosine, a substrate of adenosine deaminase, is the potentially toxic substrate in adenosine deaminase deficiency, and that the mediator of the toxic effect is dATP, a recognized potent inhibitor of ribonucleotide reductase.
References
- Biochim Biophys Acta. 1962 Dec 31;61:885-96
- Arch Biochem Biophys. 1962 Nov;99:304-12
- Biochem Biophys Res Commun. 1960 Oct;3:392-6
- Proc Natl Acad Sci U S A. 1977 Dec;74(12):5677-81
- J Pediatr. 1977 Jul;91(1):48-51
- Biochem Pharmacol. 1976 Dec 15;25(24):2713-9
- Cell. 1976 Oct;9(2):205-11
- Adv Exp Med Biol. 1977;76A:326-40
- N Engl J Med. 1976 Dec 23;295(26):1449-54
- Arch Biochem Biophys. 1976 Nov;177(1):10-5
- N Engl J Med. 1976 Dec 9;295(24):1337-43
- J Pediatr. 1976 Nov;89(5):732-6
- Lancet. 1972 Nov 18;2(7786):1067-9
- Biochim Biophys Acta. 1969 Oct 7;192(1):141-4
- J Biol Chem. 1972 Sep 10;247(17):5477-85
- Lancet. 1972 Dec 16;2(7790):1316
- Mol Pharmacol. 1972 Jul;8(4):410-6
- Biochemistry. 1974 Aug 13;13(17):3601-6
- Cell. 1974 Dec;3(4):367-74
- Proc Natl Acad Sci U S A. 1973 Nov;70(11):3099-102
- Mol Pharmacol. 1969 Jul;5(4):358-75
- Proc Soc Exp Biol Med. 1970 Apr;133(4):1361-5
- J Biol Chem. 1970 Oct 25;245(20):5360-8
- Lancet. 1975 Oct 18;2(7938):743-6
- Lancet. 1975 Nov 1;2(7940):850-3
- Lancet. 1975 May 3;1(7914):1010-3
- FEBS Lett. 1976 Jul 1;66(1):102-6
- Science. 1975 Mar 14;187(4180):957-9
- J Clin Invest. 1976 Feb;57(2):274-82
- Cell Immunol. 1974 Jun;12(3):387-95
- Pediatr Res. 1976 Jul;10(7):642-6
- J Pediatr. 1974 Feb;84(2):173-7
- Science. 1973 Nov 23;182(4114):836-7
- Biochim Biophys Acta. 1969 Feb 18;174(2):585-90
- N Engl J Med. 1975 Apr 3;292(14):714-9
- Proc Natl Acad Sci U S A. 1976 Aug;73(8):2867-71
- J Clin Invest. 1976 Apr;57(4):1025-35
- J Biol Chem. 1976 Jul 10;251(13):4055-61
- Biochem Pharmacol. 1975 Aug 15;24(16):1495-8
- Pediatr Res. 1976 Jan;10(1):67-70
- Biochem Pharmacol. 1975 Jan 1;24(1):154-6
- Biochem Pharmacol. 1975 Mar 15;24(6):693-701
- J Biol Chem. 1966 Oct 25;241(20):4802-9
Source: PubMed